Abstract
Prostate cancer initially responds well to androgen deprivation therapies, but some tumors can progress to an androgen-independent phenotype, also known as castration-resistant prostate cancer (CRPC), leading to metastasis. The molecular mechanisms that lead to the development of CRPC are not clear. Our laboratory has shown the expression and the extranuclear localization of the estrogen …